Q3 2026 13F · SEC CIK 200406
Johnson & Johnson
CorporationFiled 2026-10-26 for Q3 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $761.7M
- Reported positions
- 15
- Top holdings a year, 3 yrs
- +52.6%
- Average holding period
- 4.3 yrs
Johnson & Johnson is a corporation that reported 15 positions worth $761.7M in its Q3 2026 13F, filed 2026-10-26. Its largest holdings were Protagonist Therapeutics Inc (PTGX, 45.3%), Nanobiotix (NBTX, 23.0%), Meiragtx Hldgs PLC (MGTX, 9.6%). A portfolio copying its top holdings returned 52.6% a year over the last 3 years, against 22.3% for the S&P 500.
Johnson & Johnson holdings all 15 positions.
Weights are shares of the filer's total reported 13F value, compared with Q2 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| PTGXProtagonist Therapeutics Inc | 45.3% | +0.0% | $345.1M |
| NBTXNanobiotix | 23.0% | +0.0% | $175.2M |
| MGTXMeiragtx Hldgs PLC | 9.6% | +0.0% | $73.1M |
| RAPPRapport Therapeutics Inc | 7.9% | +0.0% | $60.0M |
| CTNMContineum Therapeutics Inc | 3.5% | +0.0% | $26.6M |
| CBRSCerebras Systems Inc | 3.0% | +140.1% | $22.9M |
| XNCRXencor Inc | 2.5% | +0.0% | $18.7M |
| LEGNLegend Biotech Corp | 2.1% | +0.0% | $16.2M |
| FATEFate Therapeutics Inc | 1.1% | +0.0% | $8.0M |
| CVRXCvrx Inc | 0.9% | +0.0% | $7.0M |
| PRCTProcept Biorobotics Corp | 0.9% | +0.0% | $6.5M |
| NMRANeumora Therapeutics Inc. | 0.1% | +0.0% | $1.1M |
| VORVor Biopharma Inc | 0.1% | +0.0% | $1.0M |
| FLDMStandard Biotools Inc | 0.0% | +0.0% | $231K |
| ACETAdicet Bio Inc | 0.0% | +0.0% | $163K |
What Johnson & Johnson bought and sold in Q3 2026, against Q2 2026.
New positions
No new positions among the largest holdings.
Added to
- CBRS Cerebras Systems Inc+140.1% shares
Reduced
No position shrank by more than 5%.
Sold out
Nothing sold out.
Share counts compared with the Q2 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +30.1% /yr
- S&P 500 +11.7%
- 3 years
- +52.6% /yr
- S&P 500 +22.3%
- 5 years
- +10.1% /yr
- S&P 500 +10.3%
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q3 2026 | $761.7M | 15 |
| Q2 2026 | $798.7M | 15 |
| Q1 2026 | $652.4M | 16 |
| Q4 2025 | $555.0M | 17 |
| Q3 2025 | $503.9M | 20 |
| Q2 2025 | $334.1M | 20 |
| Q1 2025 | $341.9M | 20 |
| Q4 2024 | $386.1M | 20 |
| Q3 2024 | $427.3M | 20 |
| Q2 2024 | $400.7M | 20 |
| Q1 2024 | $4.4B | 22 |
| Q4 2023 | $4.4B | 23 |
Questions about Johnson & Johnson's portfolio
What stocks does Johnson & Johnson own?
Johnson & Johnson's latest 13F, for Q3 2026 and filed Oct 26, 2026, lists 15 positions worth $761.7M. The largest are Protagonist Therapeutics Inc (PTGX) at 45.3%, Nanobiotix (NBTX) at 23.0%, Meiragtx Hldgs PLC (MGTX) at 9.6%, Rapport Therapeutics Inc (RAPP) at 7.9% and Contineum Therapeutics Inc (CTNM) at 3.5%.
What did Johnson & Johnson buy last quarter?
In Q3 2026, Johnson & Johnson added Cerebras Systems Inc (CBRS) (+140.1% shares), compared with its Q2 2026 filing.
What did Johnson & Johnson sell last quarter?
Johnson & Johnson sold out of nothing and cut no large position by more than 5% in Q3 2026.
How has Johnson & Johnson's portfolio performed?
A portfolio copying Johnson & Johnson's 20 largest 13F holdings each quarter, from the day each filing was public, returned +52.6% a year over the last 3 years, against +22.3% for the S&P 500. Over 1 year: +30.1% against +11.7%. Over 5 years: +10.1% a year against +10.3%.
When is Johnson & Johnson's next 13F filing due?
13F filings are due 45 days after each quarter ends. Johnson & Johnson's filing for the quarter ending Dec 31, 2026 is due by Feb 14, 2027; this page updates the day after it is published.